Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • jvanleuven
    Member
    • Nov 2011
    • 23

    #16
    well, there are probably at least two genomes in there and lots of contaminating host DNA. One genome is pretty easy because it has >95% sequence identity to an annotated genome. The other is more of a challenge b/c is likely quite diverged from anything else. both are under 500kb in length.

    jt

    also i tried aggressive filtering. reads >50bp, quality >30 for 100% of the read.
    cut it down to 5 million PE reads. didn't help. did lower the coverage of the more abundant genome accordingly, but also reduced the contig lengths and didn't effect the number of Ns in the contigs.
    Last edited by jvanleuven; 11-04-2011, 12:45 PM.

    Comment

    • aloliveira
      Member
      • Aug 2010
      • 47

      #17
      cliffbeall

      I would try being very aggressive in quality filtering/trimming. Most accounts that I have seen don't see improvement beyond 50X coverage, so you should be able to be selective with your input data.
      [filter using fastx-tool kit - remove reads < 20bp in length, <30 quality over 90% of the read
      Is it a good quality filtering/trimming no?

      Comment

      • jvanleuven
        Member
        • Nov 2011
        • 23

        #18
        Not sure if that is good enough filtering, this is the first time i've tried it.

        I think it is pretty good. The first few bases and the last few bases have average qualities around 34, the rest are higher.

        Comment

        • jvanleuven
          Member
          • Nov 2011
          • 23

          #19
          Thanks for all the help. Still not sure about how to fix the N gaps created by scaffolding. I am thinking about using Cap3 to try and cover the gaps with contigs created from a single read assembly using all the quality filtered reads.

          What software may be used to map lots of shorter contigs to longer contigs to give a consensus sequence?

          Comment

          • nickloman
            Senior Member
            • Jul 2009
            • 355

            #20
            It's not really a case of fixing them as Velvet is simply telling you that it thinks two contigs are joined together with a gap of a specific length by reference to paired-end information. But it cannot fill in that gap with sequence because there is no apparent unambiguous path through the assembly graph. This is usually a result of repetitive sequence longer than the read length, but sometimes could be due to low coverage.

            Basically you have scaffolds formed of contigs (actually I wish Velvet would call the output scaffolds.fa not contigs.fa to make this more clear, or produce an AGP file, but that's another matter).

            You might find that GapCloser (part of SOAPdenovo) can be coaxed into filling some of these gaps, by performing local assemblies using pair-halves which fall within the gap region as determined by some mapping approach (http://soap.genomics.org.cn/about.html). IMAGE is another utility that does this (http://genomebiology.com/2010/11/4/R41). In my experience results are mixed and it will depend on the repeats in your genome.

            Comment

            • nickloman
              Senior Member
              • Jul 2009
              • 355

              #21
              And, PS

              Read filtering is probably not the significant factor here.

              Comment

              • jvanleuven
                Member
                • Nov 2011
                • 23

                #22
                yeah, i think my reads are sufficiently filtered. I think my problem may be a result of such widely varying coverages, or maybe variance in my insert size, or possibly lots of repeats? both genomes are AT rich (25%).

                if I can resolve some of the N gaps with single reads, my contigs are long enough.

                jt

                Comment

                • nickloman
                  Senior Member
                  • Jul 2009
                  • 355

                  #23
                  99 times out of 100 it will be due to repeats. It's normal!

                  Comment

                  • jvanleuven
                    Member
                    • Nov 2011
                    • 23

                    #24
                    Yeah, but a lot of my contigs look like this;


                    NODE_8445_length_3509_cov_38.863495
                    ATGGGATTGGAATACAAGAAGTTACTTCAAATATATAACATGTCGAACAACAAACATGGA
                    GATAATCGATATCGCTAAATCAAAGCTATCAGAAAGACATCCTGAATGTTGATTTTAAAA
                    CAATTGATAACGAAGTAATATTGGAATTGATATTCGATTTATCCAATGGTATTAAAATAA
                    ATGTTCAAGACATAGATATAAAGAAGGATATTAAGTTCTTAGAATCACGTATTGATCTAA
                    AAGATGATAAATATCAATATCAATTATACGATGGGATAACAGGTTTAAAACATGATAGAA
                    AGACAACGGTTGGAATTTATGTATGTTTATAAATTAAATCACATGGTAGATGATAAAATG
                    TATGCCAGATCTATAGGACCTTATTCAACTATTACACAACAACCACTTAAAGGTAAGTTC
                    CATAAAGGAGGACAGATGTTGGGTGAGATGGAGGTATGGTTGTTGTAAAGCTATGGTGTT
                    GCATTCGTTACAAACGAAGCATTGACCGCTAAATGTGATGATATTCAAGCATGAAACAAA
                    TTGCATGATAACATGTTATTCGGTACACCATTGNNNNNNNNNNTTTAGATTAGTAATGTT
                    GTATGGCTTTAGATTAGTAATGTTGTATGGTGATTCGATTTTGTTATTAAAATATGATGT
                    TAATTTATGATTATTGATTATAAAGAATAGCGACAAGTTGTAATATTATTGGTATGANNN
                    NNNNNNNGAGTTAACGATAGCCTCTCCAGAGGCTACAATGACCTATTCTTGGGGAGAGGT
                    ATACAACGGTATTGGGTTCGATTTTGTTGTTAAAATATGATGTTAATTTGTGATTATTGA
                    TTATAAAGAATAGTGACAAGTTGTAATATTATTGGTATGAAAGTTATCAAGTAGTATATT
                    GTCTGTTACTAATATAATCAATGAGATATATAAACACTGTGATTTGTTAAAGGTANNNNN
                    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
                    NNNNNNNNNNNNNNNNAATTATCAACATAAGTTAATAGGTTGATTGATAAAACAACAAAT
                    TGATAGATTATTGGGTATAATTTGGTCAAANNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
                    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNAATTT
                    GAATTATTTACTCTAAATTGTATAAATCACTTGGTAATGATGGATTCAATAAATCTCTAA
                    GATAACAAACGGTTTTTATTTCTTAAATAACTATCTGATAACAAAACAGTTGCTTTAGTG
                    ATATCGTTATCAATTCTTTTCAGAAAACCTAATCGGTTGTCTTCACAAATTCCTTTAACT
                    AATTTAATCTTATTTATAAATTCCTTTCTAACTGTTCTGATACTTGTTTTATATCTTTCA
                    AACATTTTAGATAATTCATTCAAAGCAATCTTTTGTCTCTGTGTTATTATTGATGGTAAG
                    GCTTAACTTGATATGATTCCCGTTAAGTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
                    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNAATTATATCGTTTGTTCTAAGTTTACA
                    TATTGGTCGTAGTTCAATAATTGTATCAGAAAGATAAGTACATTNNNNNNNNNNGGACTT
                    CAATGATTGATTTTTTGTTGTTCTTATTTCATTAACAAGAGACATATCAAGTCTTGATGG
                    TAAAATTTTGTTTGATATAAGATCAAAATTTTTAATTTAAGTTTAATAATAATTGGTTCA
                    ATTGTATGTATATATCTTCCAATGTTAACTTTGAATAATTTGGCTTTAATTTAAACAATT
                    ATAAGAATTAGTTCAGTTCATCTAATATTCAGATGGAAATTAAACGAGAAATAACATATT
                    GAATTATAGAACAAACAATAAGAGAACCAACAATAAGATAATTTGGAATTGTAATCCAAT
                    TTAGATGAGTTTAGTTTATAAATTTTGATAATCTCTGGAATATATTAATTTAAATGCAGT
                    TGTTGGTAGAATCTNNNNNNNNNNGAAAATAATATATTGAATTATAGAATCAACAATAAG
                    ATAATTTGGGATTATAATCCAATTTAGATGAGTTTTAGTTATAAATTTTGATAATCTTTG
                    GAAGATATTAATTTAAATGCAGTTAGTTGGTAGAATTTGGAAATAAACAGATGATCTTTA
                    AATCACTATTTTTCTTAAAANNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
                    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNAATAAAATATTAACAGTTGATCAATAA
                    TTCGATATTATTAAACGAATCCAATGAAAATAAACAAGTTAATAACNNNNNNNNNNGATA
                    AAATATTAACAGTTGATCAATAATTCAATATTATTGAATGAATCCAATGAAAATAAACAA
                    GTTAATAACCAATTTTATTGGCATTGATAGATAGTTGGTTTCTATTCCTAACAAATACTT
                    GATTACTTAATAAGATTCAAAGGAGAGATAAATAACTTATGGTCCGTTTTAAACTAATTA
                    ATGATTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
                    NNNNNNNNNNNGACAATTAATAACAATTTATATCTGAATTATATTCGATTATTTTAGAAA
                    GAGATCGTTTAAAAAAAAANNNNNNNNNNTATTGATAGATAGTTGGTTCTTATTTCTAAC
                    AAATATTTGATTAGTTAATAAGTTTCAAAGGAGAGTATAATAACTTANNNNNNNNNNNNN
                    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
                    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
                    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNGATTATTTTCTCTATGT
                    TTATATTTATAATTTTCGATGAAATCATATTCTTGATAACTCTCTAATAAGAGTAATTTT
                    TAAATCTAATAATATTAAAACTCAGTTTGAGAAATTAGTTTGTTACGATCGAATATAAAT
                    TAAAATTAAGCACAACAAACCTAATAATTTTGATCAAAATTTATTAAGTGTTTAATTTAT
                    GTGTGTTAAATATTATAAATAATACTTAATTAACTTAATTTAAAAATTAATTTGTTGGTA
                    ATAATTTTTATTTTTTAATGTGTTAAGATTTATCGTATTAATTATATAATAATTTATTAT
                    TCTTAATAGAAGTAACACTAATAACTTATCGGATATTGATTGAATCTATTGAAATTGATG
                    TTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
                    NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNAGCGGTTACATATATTATTTTTGAA
                    TTGTGAGAGATATGAATTTCATTTTCTTTATTCAAAATAAACAATTATTTATTTCAATT

                    Comment

                    Latest Articles

                    Collapse

                    • SEQadmin2
                      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                      by SEQadmin2


                      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                      The systematic characterization of the human proteome has
                      ...
                      07-20-2026, 11:48 AM
                    • SEQadmin2
                      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                      by SEQadmin2



                      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                      ...
                      07-09-2026, 11:10 AM
                    • SEQadmin2
                      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                      by SEQadmin2



                      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                      07-08-2026, 05:17 AM

                    ad_right_rmr

                    Collapse

                    News

                    Collapse

                    Topics Statistics Last Post
                    Started by SEQadmin2, 07-24-2026, 12:17 PM
                    0 responses
                    29 views
                    0 reactions
                    Last Post SEQadmin2  
                    Started by SEQadmin2, 07-23-2026, 11:41 AM
                    0 responses
                    21 views
                    0 reactions
                    Last Post SEQadmin2  
                    Started by SEQadmin2, 07-20-2026, 11:10 AM
                    0 responses
                    211 views
                    0 reactions
                    Last Post SEQadmin2  
                    Started by SEQadmin2, 07-13-2026, 10:26 AM
                    0 responses
                    78 views
                    0 reactions
                    Last Post SEQadmin2  
                    Working...